Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,571.20 +0.73%
EUR-USD 1.2517 -0.1227%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 90.86 +0.22%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: EN Paris
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

BioAlliance Pharma SA

Add to Portfolio

BIO:FP

3.2200 EUR 0.0400 1.26%

As of 10:45:30 ET on 05/25/2012.

Snapshot for BioAlliance Pharma SA (BIO)

Open: 3.2300 Day's Range: 3.2000 - 3.3000 Volume: 35,981 Bid: 3.2300
Previous Close: 3.1800 52wk Range: 2.8000 - 6.3074 1-Yr Rtn: -45.18% Ask: 3.2500

Stock Chart for BIO

No chart data available.
  • BIO:FP 3.2200
  • 1D
  • 1M
  • 1Y
3.1800
Interactive BIO Chart

Previous Close

Key Statistics for BIO

Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share () (ttm) -0.8069
Est. EPS (12/2012) -
Est. PEG Ratio -
Market Cap (M EUR) 56.86
Shares Outstanding (M) 17.66
Enterprise Value (M EUR) (ttm) 42.73
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 4.4231
Price/Sale (ttm) 18.0396
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 09/21/2012
More BIO Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for BIO

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)
More BIO Income Statement Data
  • Total Assets
  • Total Liabilities (M/EUR)
  • Debt to Assets (%)
More BIO Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/EUR)
More BIO Cash Flow Data

Company Profile & Key Executives for BIO

BioAlliance Pharma is a biopharmaceutical company specialized in the development of therapeutics targeting drug resistance in cancer, HIV and other severe and opportunistic infections. The Company addresses worldwide markets in the EU, US and Asia.

Patrick LangloisChairmanJudith Christine GrecietChief Executive Officer
More Company Profile & Key Executives for BIO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements